India Gabapentin Market to grow at a steady rate During the Forecast Period
Growing epilepsy and restless
legs syndrome is expected to drive the growth of India Gabapentin market during
the forecast period.
According
to TechSci Research report, “India Gabapentin Market By Source (In-house v/s
Contract Manufacturing Organizations), By Form (Tablet, Capsule, Others), By
Strength (100 mg, 200 mg, 300 mg, 400 mg, Others), By Distribution Channel
(Online v/s Offline), By Application (Epilepsy, Neuropathic Pain, Restless Legs
Syndrome (RLS), Seizures, Others), By End User (Adult v/s Paediatric), By
Company, By Region, Forecast & Opportunities, FY2026”, the India Gabapentin market is expected to grow at a
steady rate during the forecast period. The medication is very effective in
treating hot flashes as well as neuropathic pain. Moreover, it is considered as
first line medication for treating neuropathic pain in diabetic neuropathy,
postherpetic neuralgia, and central neuropathic pain which is expected to fuel
the market growth through FY2026. Furthermore, Gabapentin is approved for
treatment of focal seizures as well as mixed seizures, thereby projected to
bode well for the market growth in the next 5 years. However, side-effects
associated with drug consumption such as sleepiness and dizziness can restrict
the market growth over the next few years. Moreover, in some severe cases, side
effects such as increased risk of suicide, aggressive behavior, and drug
reactions can occur. This can further reduce the usage and application of the
drug thereby hindering the market growth during the forecast period.
Browse XX market data Tables and XX
Figures spread through XXX
Pages and an in-depth TOC on" India Gabapentin Market "
https://www.techsciresearch.com/report/india-gabapentin-market/5163.html
The India gabapentin market is segmented based on source, form, strength,
distribution channel, application, end user, company, and region. Based on end
user, the market can be fragmented into adult v/s pediatric. The adult segment
dominated the market until 2017 and is further forecasted to maintain its
dominance during the forecast period as well. This dominance can be accredited
to the wide use of Gabapentin in adults to treat nerve pain caused by herpes
virus or shingles. The pediatric segment is expected to grow at a high CAGR in the
market during forthcoming years on account of rising use of this drug for
treating RLS in children. Based on source, the market can be categorized into in-house
v/s contract manufacturing organizations. The in-house segment dominated the
market until 2017 as most of the leading companies focus on in house production
owing to high standardization and flexibility. Contract manufacturing
organizations segment is expected to witness significant growth in the market
as it saves cost and maximize profits.
Aurobindo Pharma Ltd., Glenmark
Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., Alkem Laboratories
Ltd., Intas Pharmaceuticals Ltd., Hetero Drugs Ltd., Silverline Chemicals Ltd.,
Taj Pharmaceuticals Ltd.,
Divis Laboratories Ltd., Unnati Pharmaceuticals Pvt. Ltd. and others are some of the leading players operating in India gabapentin
market. Companies operating in the market are using strategies such as joint
ventures, product launches, mergers and research collaborations to boost their
share and increase their geographic reach.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=5163
Customers can also
request for 10% free customization on this report.
“India gabapentin market is expected to
witness growth during the forecast period as it is used to treat patients with restless
legs syndrome (RLS). In addition to this, Gabapentin medications also
prescribed for many off-label uses, including treatment of anxiety disorders, bipolar
disorder and insomnia. This is further expected to create lucrative
opportunities for the market growth of India gabapentin market over the next
five years.” said Mr. Karan Chechi, Research Director with
TechSci Research, a research based India management consulting firm.
“India Gabapentin Market By Source (In-house v/s
Contract Manufacturing Organizations), By Form (Tablet, Capsule, Others), By
Strength (100 mg, 200 mg, 300 mg, 400 mg, Others), By Distribution Channel
(Online v/s Offline), By Application (Epilepsy, Neuropathic Pain, Restless Legs
Syndrome (RLS), Seizures, Others), By End User (Adult v/s Paediatric), By
Company, By Region, Forecast & Opportunities, FY2026”, has evaluated the future growth potential of India gabapentin
market and provides statistics & information on market size, structure and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges and opportunities in India gabapentin market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]